Department of Cardiology, University Heart and Vascular Center Hamburg, Martinistr. 51, 20246 Hamburg, Germany.
Department of Cardiology, University Heart Center Cologne, Cologne, Germany.
Europace. 2023 Dec 28;26(1). doi: 10.1093/europace/euad378.
Pericardial tamponade (PT) is the most frequent severe complication during electrophysiology (EP) procedures and requires immediate, co-ordinated, and effective treatment. However, multiple aspects of PT treatment are either not standardized or are under ongoing debate.
An online questionnaire consisting of 26 multiple-choice questions was sent out to the European Heart Rhythm (EHRA) Research Network and also distributed via social media outputs. The EHRA survey was conducted between May and June 2023. A total of 213 replies were received from European (87%) and non-European countries. Ninety per cent of all participants perform interventions in dedicated EP labs equipped with different ablation platforms. In case of PT, most participants use X-ray as the main imaging modality guiding pericardial puncture, predominantly aiming for an anterior puncture site. Sheaths of different sizes are introduced into the pericardial space (84.3%), followed by a pigtail catheter. Application of protamine is an established but variable step in the majority (84.6%). Novel oral anticoagulants (NOAC) antidotes are not used by 73.3% of participants, while 15.2% routinely apply them. Re-transfusion of aspirated blood is performed by 72.1% [before protamine administration (18.2%), after protamine administration (13.5%), if pericardial effusion cannot be controlled (40.4%)]. A total of 72.4% re-transfuse without blood filter systems. A decision for surgical intervention is mostly taken if bleeding continues despite all interventional measures.
The current survey demonstrates that the management of PT is heterogeneous among centres. The findings of this survey may help to guide operators in their treatment and decisions in the setting of PT.
心包填塞(PT)是电生理(EP)程序中最常见的严重并发症,需要立即进行协调有效的治疗。然而,PT 的治疗有多个方面尚未标准化或仍存在争议。
一项包含 26 个多项选择题的在线问卷发送给了欧洲心律学会(EHRA)研究网络,并通过社交媒体进行了分发。EHRA 调查于 2023 年 5 月至 6 月进行。共收到来自欧洲(87%)和非欧洲国家的 213 份回复。所有参与者中有 90%在配备不同消融平台的专用 EP 实验室进行介入治疗。在发生 PT 的情况下,大多数参与者使用 X 射线作为引导心包穿刺的主要成像方式,主要目标是前穿刺部位。不同大小的鞘管被引入心包腔(84.3%),随后是猪尾导管。应用鱼精蛋白是大多数情况下的既定步骤,但存在差异(84.6%)。新型口服抗凝剂(NOAC)拮抗剂在 73.3%的参与者中未被使用,而 15.2%的参与者常规使用。72.1%的参与者会重新输注抽吸的血液[在使用鱼精蛋白之前(18.2%)、在使用鱼精蛋白之后(13.5%)、如果无法控制心包积液(40.4%)]。共有 72.4%的参与者在没有血液过滤系统的情况下重新输血。如果尽管采取了所有介入措施但仍持续出血,则大多数情况下会选择手术干预。
目前的调查表明,PT 的管理在各个中心之间存在差异。本调查结果可能有助于指导操作者在 PT 情况下进行治疗和决策。